Search

Your search keyword '"Facheris, Maurizio"' showing total 200 results

Search Constraints

Start Over You searched for: Author "Facheris, Maurizio" Remove constraint Author: "Facheris, Maurizio"
200 results on '"Facheris, Maurizio"'

Search Results

1. Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

2. Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance

3. Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

4. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial

7. Living with Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa for Symptom Management in Advanced Parkinson’s Disease: A Patient Experience Study (P9-3.006)

8. Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease:Considerations for initiation and maintenance

9. Improved Sleep Correlates with Improved Quality of Life and Motor Symptoms with Foslevodopa/Foscarbidopa.

10. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

13. Comparability of Foslevodopa/Foscarbidopa Pharmacokinetics in Healthy Asian and White Participants.

14. Safety and Efficacy of 24-Hour/Day Subcutaneous Infusion of Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease During a Phase 3 Study: 6-Month Interim Results (S16.009)

25. Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease

28. A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants

29. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)

34. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study

38. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease

39. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure

40. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)

42. Critical Path for Parkinson’s: Catalyzing Innovation for Parkinson’s Clinical Trials through Data Sharing and Regulatory Science (P2.8-010)

43. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure

44. Rationale and Design of an Open-Label, Randomized, 26-Week Study Comparing Levodopa-Carbidopa Intestinal Gel to Optimized Medical Treatment on Non-Motor Symptoms in Patients with Advanced Parkinson’s Disease – INSIGHTS Study (P2.048)

46. Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease

47. Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson’s disease

49. Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem

Catalog

Books, media, physical & digital resources